Acquisition of Gracell completed
AstraZeneca today announced the successful completion of the acquisition of Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering AstraZeneca’s cell therapy ambition. The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F, a novel, clinical-